Revitope is an early stage biotechnology company focused on developing the next-generation of T cell redirecting biologics.
Immune-based therapies are redefining how cancer is treated as clinical studies demonstrate unprecedented deep and durable responses in multiple cancers. In particular redirecting T cells to tumors is a successful strategy for immunotherapy of liquid tumors. However, unleashing a potent immune response that is entirely focused on the tumor continues to be elusive.
Revitope is developing a new class of biologic prodrugs we call Programmable Antibody Circuits or PACs that are engineered to focus immune activation to the cancer cell surface while expanding the antigenic targeting space.
Company Details
- Employees
- 7
- Founded
- -
- Address
- 610 Main Street, Cambridge,massachusetts,united States
- in****@****ope.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- revitope.com
- Keywords
- Immuno-oncology and Biologics.
- HQ
- Cambridge, Massachusetts
Revitope Questions
Revitope's website is revitope.com
Revitope's LinkedIn profile is https://www.linkedin.com/company/revitope
Revitope has
7 employees.
View email and phone details for 7
employees at Revitope.
Revitope's industry is
Biotechnology Research
Revitope's top competitors are
Gt Biopharma, Inc.,
Oncomatryx Biopharma,
Spero Therapeutics,
Immunogen, Inc.,
Naya Therapeutics,
Gritstone Bio,
Abdera Therapeutics,
Compass Therapeutics Inc.,
Gigamune,
Genmab.
Revitope's support email address is info@revitope.com
Revitope's categories are Biotechnology Research
Revitope's founding year is 2016
